An entrepreneur and 25-year veteran of the software and computer industries, MIT Media Lab director Frank Moss has spent his career bringing innovative business technologies to market.
In the last five years, however, he's been seeking something different: how to make a broader contribution to the world by using technology to address pressing social issues—such as health care—and to improve quality of life for people worldwide.
Most recently, he co-founded and is on the board of Infinity Pharmaceuticals, Inc., an early-stage cancer-drug discovery company doing innovative work at the intersection of technology and the life sciences. In addition, he chaired the advisory council for the creation of the Systems Biology Department at Harvard Medical School, where he remains an advisor.
During his career in the computer and software industries, Moss served as CEO and chairman of Tivoli Systems Inc., a pioneer in the distributed systems management field, which he took public in 1995 and subsequently merged with IBM in 1996. He co-founded several other companies, including Stellar Computer, Inc., a developer of graphic supercomputers, and Bowstreet, Inc., a pioneer in the emerging field of Web services.
He began his career at IBM's scientific center in Haifa, Israel, where he also taught at the Technion, Israel Institute of Technology. He later held various research and management positions at IBM's Yorktown Heights (NY) Research Center, working on advanced development projects in the areas of networking and distributed computing, as well as executive management positions at Apollo Computer, Inc., and Lotus Development Corporation.
Moss is a member of the Advisory Council for the School of Engineering and Applied Sciences at Princeton University.
He received a BS in aerospace and mechanical sciences from Princeton University, and both his MS and PhD in aeronautics and astronautics from MIT. His citations include Ernst & Young's Entrepreneur of the Year award and Forbes Magazine's "Leaders for Tomorrow."
The battle is over and the final economic recovery and stimulus bill preserves $15 billion for basic science and over $50 billion for upgrading America’s technology infrastructure. These expenditures will put... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.